Free Trial
NASDAQ:PPBT

Purple Biotech (PPBT) Stock Price, News & Analysis

Purple Biotech logo
$2.30 +0.03 (+1.32%)
Closing price 08/22/2025 03:53 PM Eastern
Extended Trading
$2.28 -0.02 (-0.91%)
As of 08/22/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Purple Biotech Stock (NASDAQ:PPBT)

Key Stats

Today's Range
$2.17
$2.40
50-Day Range
$2.08
$2.78
52-Week Range
$2.00
$13.95
Volume
18,242 shs
Average Volume
29,662 shs
Market Capitalization
$5.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00
Consensus Rating
Buy

Company Overview

Purple Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

PPBT MarketRank™: 

Purple Biotech scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Purple Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Purple Biotech has received no research coverage in the past 90 days.

  • Read more about Purple Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Purple Biotech are expected to decrease in the coming year, from ($0.83) to ($1.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Purple Biotech is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Purple Biotech is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Purple Biotech has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.22% of the float of Purple Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Purple Biotech has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Purple Biotech has recently increased by 19.31%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Purple Biotech does not currently pay a dividend.

  • Dividend Growth

    Purple Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.22% of the float of Purple Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Purple Biotech has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Purple Biotech has recently increased by 19.31%, indicating that investor sentiment is decreasing significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Purple Biotech insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 2.98% of the stock of Purple Biotech is held by insiders.

    • Percentage Held by Institutions

      Only 9.64% of the stock of Purple Biotech is held by institutions.

    • Read more about Purple Biotech's insider trading history.
    Receive PPBT Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter.

    PPBT Stock News Headlines

    This stock could leave NVDA in the dust
    Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
    See More Headlines

    PPBT Stock Analysis - Frequently Asked Questions

    Purple Biotech's stock was trading at $4.69 on January 1st, 2025. Since then, PPBT stock has decreased by 51.0% and is now trading at $2.30.

    Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) issued its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.19.

    Shares of Purple Biotech reverse split before market open on Tuesday, September 17th 2024.The 1-20 reverse split was announced on Friday, September 13th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

    Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Purple Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Broadcom (AVGO), GE Aerospace (GE), Adobe (ADBE) and Catalyst Pharmaceuticals (CPRX).

    Company Calendar

    Last Earnings
    8/06/2025
    Today
    8/24/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:PPBT
    Previous Symbol
    NASDAQ:KTOV
    CIK
    1614744
    Employees
    20
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $33.00
    Low Price Target
    $33.00
    Potential Upside/Downside
    +1,334.8%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($0.42)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$7.24 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    -14.00%
    Return on Assets
    -12.52%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    2.88
    Quick Ratio
    2.88

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $12.73 per share
    Price / Book
    0.18

    Miscellaneous

    Outstanding Shares
    2,590,000
    Free Float
    2,509,000
    Market Cap
    $5.96 million
    Optionable
    Optionable
    Beta
    0.49
    The 10 Best AI Stocks to Own in 2025 Cover

    Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

    Get This Free Report

    This page (NASDAQ:PPBT) was last updated on 8/25/2025 by MarketBeat.com Staff
    From Our Partners